Menarini has partnered with Oxford BioTherapeutics (OBT) to develop a portfolio of antibody-based drugs in the field of cancer. The collaboration includes five of OBT’s antibody and antibody-drug conjugate (ADC) programmes, each addressing a different oncology target. Once proof-of-concept has been achieved, Menarini will complete clinical development and commercialise the products in Europe, the CIS, Asia and Latin America while OBT retains rights in North America and Japan. The deal represents an attempt by Menarini to replenish its biologics pipeline after the Phase III development failure of abagovomab for advanced ovarian cancer.